JAZZ - Spark Newswire

1 minute read

Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer

January 19, 11:58 AM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Zymeworks Inc (NASDAQ:ZYME) announced tolerability and efficacy results, including the first overall survival (OS) data, from…

JAZZ

2 minute read

Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey’s District Court

By Joana Scopel

January 5, 6:45 PM

Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS

GWPH

3 minute read

Legal
News

‘Pharma Company Behind FDA-Approved CBD Drug Sues A Dozen Competitors Over Alleged Patent Infringement’ – Marijuana Moment

By Benzinga Newsdesk

January 5, 1:52 PM

https://www.marijuanamoment.net/pharma-company-behind-fda-approved-cbd-drug-sues-a-dozen-competitors-over-alleged-patent-infringement/ The drug company behind the CBD-based medication Epidiolex has filed a lawsuit

JAZZ

1 minute read

FDA
News

Jazz Pharmaceuticals Says On Jan. 3, Co. Filed Patent Infringement Suit Against ANDA Filers In U.S. District Court For District Of New Jersey; Says As A Result Of Lawsuit A Stay Of Approval Of Up To 30 Months Will Imposed By FDA On ANDA Filers’ ANDAs

By Michael Horton

January 4, 6:33 PM

-SEC Filing

JAZZ

2 minute read

Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

December 21, 8:47 PM

U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation expectations fell to their lowest level since Sept. 2021, at 6.7%, according to Reuters.

AMZN

1 minute read

Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks

By Vandana Singh

December 21, 2:57 PM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) exercised its option to continue with its exclusive development and commercialization rights to Zymeworks Inc’s (NASDAQ:ZYME) zanidatamab in key…

JAZZ

1 minute read

Analyst Ratings

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals

By Benzinga Insights

December 9, 8:03 AM

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

JAZZ

1 minute read

Goldman Sachs Upgrades Jazz Pharmaceuticals to Buy, Lowers Price Target to $190

By Benzinga Newsdesk

December 9, 6:51 AM

Goldman Sachs analyst Madhu Kumar upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) from Neutral to Buy and lowers the price target from $192 to $190.

JAZZ

3 minute read

Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy

By Vuk Zdinjak

December 5, 9:59 AM

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers of adult and pediatric

JAZZ

2 minute read

Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling

By Lisa Levin

November 28, 8:40 AM

The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

Feed Symbols: JAZZ